 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Hanmi Pharmaceutical surpassed KRW 1 trillion in cumulative sales in the third quarter for the first time since its establishment.
Hanmi Pharmaceutical made an announcement on the 1st that its tentative sales in the third quarter rose 6.6% year-on-year to 364.6 billion won. Operating profit and net profit grew 22.9% and 93.5%, respectively, to 57.5 billion won and 60.5 billion won.
Cumulative sales in the third quarter reached 1.685 trillion won, up 9.0 percent from 980.3 billion won a year earlier. Behind the growth in performance is a lineup of specialized drugs centered on improvement and complex new drugs.
Hanmi Pharmaceutical achieved 230.5 billion won in sales outside of the country (based on UBIST) in the third quarter alone, up 9.3 percent from a year earlier. In particular, sales of 'Rosujet', a complex new drug for dyslipidemia grew 19.8% year-on-year to 45.5 billion won, and 'Amosaltan Family', a composite new drug product group for high blood pressure drugs, grew 3.5% to 35.2 billion won.
The company expects to maintain its No. 1 spot in overseas prescription sales in Korea this year, which it has kept for five consecutive years since 2018.
Local subsidiaries in China also led the positive performance. Beijing Hanmi Pharmaceutical achieved sales of 93.3 billion won in the third quarter. Operating profit grew 7.7% to 26 billion won and net profit grew 7.1% to 23.8 billion won.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
